A comprehensive review on liraglutide and novel nanocarrier-based systems for the effective delivery of liraglutide.

Abstract

Glucagon-like peptide-1 (GLP-1) analogs are synthetic derivatives of the natural incretin hormone GLP-1, which plays a crucial role in glucose metabolism. These analogs mimic the function of endogenous GLP-1 by stimulating insulin secretion, suppressing glucagon release, delaying gastric emptying, and promoting satiety, making them effective for managing type 2 diabetes mellitus (T2DM) and obesity. Liraglutide, a glucagon-like peptide-1 (GLP-1) analog, has gained considerable attention for its potential in treating type 2 diabetes mellitus, obesity, and cardiovascular disorders. However, its therapeutic application is significantly hindered by poor absorption, a short biological half-life, and unintended off-target effects, necessitating advanced drug delivery strategies. To address these challenges, various nanocarrier-based systems-such as nanofibers, liposomes, polymeric nanoparticles, exosomes, hydrogels, and lipid nanoparticles-have been explored. These nanocarriers facilitate site-specific and sustained release of liraglutide, improving its bioavailability and therapeutic efficacy. This article provides a comprehensive overview of liraglutide's pharmacological properties, preclinical studies, and the potential of different nanocarrier-based approaches in optimizing its delivery for enhanced clinical outcomes.